If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Lucy Vivash is a Research Fellow in the Department of Neuroscience, Monash University.

My research focuses on the application of neuroimaging (particularly PET imaging) to better understanding neurological and neurodegenerative diseases. I have several ongoing preclinical and clinical projects aim at the development and application of novel PET radiotracers for a range of neurodegenerative and neurologiical conditions.
I have a significant interest in the role of tau in neurodegenerative diseases. This has lead to numerous clinical trials in neurodegenerative diseases investigating the use of sodium selenate as an anti-tau therapy. I am also interested in the development of biomarkers to better identify tauopathies.




All projects are available research students

Tau-PET imaging in progressive supranuclear palsy
This project (in collaboration with industry partners) seeks to investigate the utility of a novel PET radiotracer to image tau in the living brain in patients with Progressive Supranuclear Palsy

Tau-PET imaging in animal models of neurological diseases
This project seeks to investigate whether tau is present in the pathogenesis of a number of neurological conditions including stroke and epilepsy

Development of radiotracers to target MerTK
This project aims to develop new radiotracers that specifically target MerTK, a protein expressed on neurprotective microglia, which is implicated in the pathogenesis of multiple sclerosis.

Monash Cognition Imaging Study (MCIS): Characterising Mild Cognitive Impairment using multimodal biomarkers
This project aims to utilise imaging (MRI, FDG-PET and amyloid-PET), cognitive and biofluid biomarkers to better understand the differing presentations of mild cognitive impairment

Sodium selenate as a disease-modifying treatment for tauopathies
These projects evaluate the safety and efficacy of sodium selenate as a disease-modifying treatment for tauopathies. A phase 1b study in behavioural variant frontotemporal dementia is due to complete in Dec 2020. Two phase 2 studies are due to begin in early 2021, in progressive supranuclear palsy and behavioural variant frontotemporal dementia.



Research area keywords

  • Neurodegenerative Diseases/Disorders
  • Neuropharmacology
  • Progressive Supranuclear Palsy
  • Neuroimaging
  • Position Emission Tomography (PET)


Recent external collaboration on country level. Dive into details by clicking on the dots or
If you made any changes in Pure these will be visible here soon.